J.P. Morgan: CXOs Win on Certainty, Biotech Awaits Catalysts

Overview

Based on four days of buy-side meetings in mainland China in early August, J.P. Morgan summarizes the latest market sentiment in the China healthcare sector. The core conclusion is: although industry fundamentals in H2 2026 remain robust, especially in innovative drug-related sub-sectors, stock price performance will be determined primarily by capital flows and risk appetite rather than fundamental increments alone. In this context, CXOs have become the first choice for 'certainty' due to high earnings visibility, while the biotech sector, despite recognized innovation capabilities, lacks a unified market narrative theme, making stock selection more important than betting on the sector.

Core views

Capital flows replace fundamentals as the core variable for short-term pricing. Most investors believe that H2 2026 China healthcare fundamentals will remain stable, particularly in innovative drug-related areas, but the driver of excess returns has shifted from 'whether demand and innovation continue' to 'whether the market cares about these fundamentals.' This means that good earnings data alone is no longer sufficient to drive stock prices; the market needs clearer catalysts, upside revisions, or globally universal narrative logic. Therefore, ETF/institutional capital flows, risk re-evaluation by generalist investors, and overseas capital movements have become tracking indicators as important as product cycles. The CXO sector receives the highest attention due to its 'certainty' premium. In approximately 20 one-on-one meetings, CXOs were repeatedly labeled as a 'certainty basket,' being the sub-sector with the highest earnings visibility. Discussions focused on liquid, benchmark-strong targets such as WuXi AppTec, WuXi Biologics, and GenScript. Investors value their repeatability in a global context and clear operational paths. GenScript is also viewed as a beneficiary of AI drug discovery (AIDD). The current debate focus for CXOs is on earnings trajectories and the degree of resolution of known risks, rather than industry status itself. Biotech sector innovation strength is recognized, but lack of a 'capital-attracting theme' constrains generalist capital entry. Investors generally acknowledge that Chinese pharmaceutical companies possess real innovation capabilities, and H1 BD transaction flows exceeded expectations. However, they point out that H2 2026 lacks a unified theme capable of attracting large-scale generalist funds like the past GLP-1 boom. This leads investment logic to shift from thematic 'basket' allocations to individual stock selection, with Kelun-Biotech, Innovent Biologics, BeiGene, and Hengrui Medicine frequently mentioned. The report argues that without a strong magnetic theme, individual stock differentiation is more critical than sector Beta. Overseas capital still has concerns about the global transferability of Chinese clinical data, with sac-TMT potentially becoming a key verification point. Overseas investors repeatedly question whether Chinese clinical data can meet the requirements of global regulators, partners, and end markets. This uncertainty directly suppresses valuation multiples for innovative assets. The report points out that unless repeated, clear proof points are seen, large incremental overseas capital inflows are unlikely. The potential release of global Phase 3 data for sac-TMT and FDA BLA acceptance in H2 2026 are viewed as key unlocking variables to answer this question. AI Drug Discovery (AIDD)热度高但投资框架尚在构建。AIDD持续引发好奇，但对话迅速从“令人兴奋”转向“如何投资”。市场对何为可防御的差异化（平台vs管线、数据护城河vs模型能力）、价值归属（工具商vs混合生物技术公司vs传统药企）尚无共识，且难以将AIDD映射到传统估值里程碑中。目前该领域仍处于“框架构建”模式，预计仅在出现具体实证时才会迎来阶段性关注。 Offline pharmacies show defensive value, with recovery expectations for consumer healthcare delayed. Offline pharmacy retail is viewed as a defensive holding within the healthcare sector due to improving same-store sales growth. Some investors believe that hospital anti-corruption measures may push prescription volumes toward retail pharmacies, benefiting leading chains. In contrast, the timeline for the recovery of elective services such as refractive surgery and adult orthodontics has been delayed by some clients to H2 2027. Targets with overseas expansion logic and reduced dependence on domestic consumption (such as Gushengtang) are more favored.

Analysis framework

The report adopts an analysis method of 'buy-side sentiment survey + structural attribution.' Institutions conduct intensive one-on-one buy-side meetings, not limited to collecting views on company fundamentals, but focusing on identifying where investors' current 'pricing anchors' lie. The analytical主线 shifts from traditional 'supply/demand/pipeline' to 'capital behaviorism': first confirming that robust fundamentals are a consensus background, then stripping out the variables that truly affect marginal pricing (capital flows > fundamentals), and classifying them by sub-sector characteristics into 'certainty assets' (CXOs) or 'awaiting-catalyst assets' (Biotech). Simultaneously, for emerging themes (AIDD) and external constraints (data going global, anti-corruption), institutions focus on evaluating their 'operability' and 'framework maturity' in current portfolios, rather than just technological prospects, thereby deriving practical conclusions that stock selection beats track selection.

Methodology notes

• Event Gaming & Behavioral FinanceCapital Flow / Chip Analysis

  Capital flows and risk appetite as dominant factors for short-term pricing

  When industry fundamentals have reached a consensus and change little, marginal stock price fluctuations are often determined by cross-sector rotation of existing capital and new entry of generalist capital. Based on this, the report judges that in the current window lacking strong catalysts, tracking ETF inflows, institutional position adjustments, and overseas capital movements explains short-term ups and downs better than tracking product approvals.

• Competition & Strategy FrameworkMoat / competitive advantage

  'Certainty' as a scarce asset attribute

  In environments with high macro or policy uncertainty, assets with clear earnings paths, global operational validation, and high liquidity are awarded a 'certainty premium.' Defining CXOs as a 'certainty basket' is based on the repeatability of their business models and the hedgability of their risk exposures, making them the first choice when capital seeks safety or stable allocation.

• Industry/Industrial Analysis FrameworkPenetration S-curve

  Investment framework for new technologies/therapies lags behind technical hype

  For emerging fields like AI drug discovery, market sentiment often precedes the maturity of valuation systems. Before recognized differentiation standards and quantifiable milestones exist, investment behavior exhibits 'event-driven' characteristics rather than trend-based allocation. Based on this, the report warns that AIDD is currently in a framework construction phase and requires specific proof points to form sustained trends.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Kelun-Biotech (6990.HK)

  One of the top biotech picks

  Strengths

  Possesses differentiated pipeline and BD potential, fitting the individual stock selection logic

  Comparison

  Frequently discussed alongside Innovent, BeiGene, and Hengrui, distinct from sector-wide allocation

  Risks

  Individual stock performance divergence intensifies under the lack of a unified capital-attracting theme

• Innovent Biologics (1801.HK)

  One of the top biotech picks

  Strengths

  Combines commercialization capability with innovative pipelines, high market attention

  Comparison

  Part of name-specific discussion scope, not thematic basket allocation

  Risks

  Needs to continuously produce upside catalysts to maintain valuation

• WuXi AppTec (603259.SS / 2359.HK)

  Core target for CXO certainty trades

  Strengths

  Good liquidity, strong benchmark attributes, clear operational path

  Weaknesses

  Geopolitical risk remains a long-term overhang

  Comparison

  Together with WuXi Biologics, a focal point of CXO discussion, superior to other vertical fields

  Risks

  Resolution progress of known risks falls short of expectations

• WuXi Biologics (2269.HK)

  Core target for CXO certainty trades

  Strengths

  One of the global CDMO leaders, high earnings visibility

  Comparison

  Together with WuXi AppTec, constitutes the CXO 'certainty basket'

  Risks

  Fluctuations in global financing environment affect orders

• MicroPort Robot (2252.HK)

  Top pick in surgical robot niche track

  Strengths

  Representative enterprise of domestic surgical robots, possesses differentiated positioning

  Comparison

  Specifically highlighted as favored in medical equipment sub-sectors

  Risks

  Commercialization ramp-up pace and medical insurance payment policies

Key data

• Buy-side Meeting SessionsApproximately 20 1x1 meetingsCovering mainstream buy-side institutions in mainland China, reflecting current mainstream market sentiment
• Top Sub-sectorsBiotech, CXORanked comprehensively based on certainty and innovation strength
• Consumer Healthcare Recovery ExpectationDelayed to H2 2027Some clients have extended the timeline for the recovery of elective service demand from previous expectations
• Key Catalystsac-TMT Global Ph3 Data / FDA BLA AcceptanceViewed as a key node to verify the global transferability of Chinese clinical data

Impact & implications

The report believes that the current market environment raises the threshold for obtaining excess returns: having 'good earnings' is not enough; there must be 'catalysts that attract market attention.' The implication for investors is: in the CXO sector, positions can be continued to capture certainty returns; in the biotech sector, the mindset of 'buying the track' should be abandoned in favor of selecting individual stocks with unique data readouts, BD execution, or global validation capabilities; for sectors like AIDD and consumer healthcare, patience is required, waiting for framework maturity or clear demand inflection points before adding positions. Meanwhile, anti-corruption and geopolitical issues, although not fully reflected in current pricing, remain tail risks to watch out for from year-end to early 2027.

Risks

• Anti-corruption campaigns may cause persistent friction in local areas (e.g., hospital access, promotion intensity), distorting sales behavior
• Geopolitical risks may reignite from late 2026 to early 2027, independent of company fundamentals
• If the global transferability of Chinese clinical data cannot be verified, it will continue to suppress innovative drug valuations
• AI drug discovery valuation framework is not yet mature, posing a risk of disappointed expectations
• Recovery of consumer healthcare service demand may be further delayed

What to watch

• Release of sac-TMT global Phase 3 data and FDA BLA acceptance progress
• ETF/institutional capital flows and changes in generalist investor risk appetite
• Marginal shifts in overseas investors' attitudes toward Chinese clinical data
• Emergence of specific proof points in the AI drug discovery field
• Trends in same-store sales growth for offline pharmacies and the effect of prescription outflow
• Geopolitical and anti-corruption policy dynamics from late H2 2026 to early 2027